Sotac Pharma.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0O2D01012
  • NSEID: SOTAC
  • BSEID:
INR
111.00
0.00 (0.00%)
BSENSE

Jun 08, 03:30 PM

BSE+NSE Vol: 1200

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Concord Drugs
Godavari Drugs
Smruthi Organic
Vaishali Pharma
Tyche Industries
Sotac Pharma.
Bal Pharma
Mercury Labs
Denis Chem Lab
Pharmaids Pharma
Balaxi Pharma

Why is Sotac Pharmaceuticals Ltd ?

1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
  • Poor long term growth as Net Sales has grown by an annual rate of 9.30% over the last 5 years
2
Flat results in Jun 24
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sotac Pharma. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Sotac Pharma.
-7.5%
-0.19
39.81%
Sensex
-10.54%
-0.81
13.06%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
9.30%
EBIT Growth (5y)
35.92%
EBIT to Interest (avg)
2.52
Debt to EBITDA (avg)
2.75
Net Debt to Equity (avg)
0.62
Sales to Capital Employed (avg)
1.30
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
16.79%
ROCE (avg)
11.27%
ROE (avg)
10.55%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
2.08
EV to EBIT
30.89
EV to EBITDA
18.96
EV to Capital Employed
1.67
EV to Sales
1.53
PEG Ratio
NA
Dividend Yield
0.09%
ROCE (Latest)
5.40%
ROE (Latest)
8.11%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Loading Valuation Snapshot...

Here's what is working for Sotac Pharma.

Profit After Tax (PAT) - Nine Monthly
At Rs 4.13 cr has Grown at 46.32 %
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Profit After Tax (PAT) - Nine Monthly
Higher at Rs 4.13 Cr
than preceding 12 month period ended Jun 2024 of Rs 3.47 cr
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)